Entecavir


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Chronic hepatitis B
Adult: Compensated liver disease: Nucleoside treatment-naive patients: 0.5 mg once daily; Lamivudine-refractory patients: 1 mg once daily. Decompensated liver disease patients: 1 mg once daily.
Child: Dosage recommendations may vary among countries. Refer to specific product guidelines.
Suy thận
Nucleoside treatment-naive patients:
CrCl (mL/min) Dosage 
<10
0.05 mg once daily or 0.5 mg every 5-7 days. 
10-29
0.15 mg once daily or 0.5 mg every 72 hours. 
30-49
0.25 mg once daily or 0.5 mg every 48 hours.
≥50
0.5 mg once daily. 

Lamivudine-refractory or decompensated liver disease patients:
CrCl (mL/min) Dosage
<10
0.1 mg once daily or 0.5 mg every 72 hours.
10-29
0.3 mg once daily or 0.5 mg every 48 hours.
30-49
0.5 mg once daily.
≥50
1 mg once daily.

Patient on haemodialysis or CAPD: Nucleoside treatment-naive patients: 0.05 mg once daily or 0.5 mg every 5-7 days. Lamivudine-refractory or decompensated liver disease patients: 0.1 mg once daily or 0.5 mg every 72 hours. Dosage recommendations may vary among countries. Refer to country-specific product guidelines.
Cách dùng
May be taken with or without food. For patients w/ compensated liver disease & nucleoside treatment-naïve, take w/ or w/o food.
Should be taken on an empty stomach. For patients w/ decompensated liver disease or w/ compensated liver disease who are lamivudine-refractory, take on an empty stomach more than 2 hr before or 2 hr after meals.
Chống chỉ định
Hypersensitivity.
Thận trọng
Patient with risk factors for liver disease (e.g. prolonged nucleoside inhibitor use, obesity, female gender); HIV co-infection. Liver transplant recipient. Not for use in HIV/hepatitis B virus co-infected patients not receiving HAART. Renal and hepatic impairment. Children. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: HIV resistance (patients with untreated HIV infection or without highly active antiretroviral therapy [HAART]).
Gastrointestinal disorders: Nausea, vomiting, diarrhoea, dyspepsia.
General disorders and administration site conditions: Fatigue.
Nervous system disorders: Headache, dizziness, somnolence.
Psychiatric disorders: Insomnia.
Skin and subcutaneous tissue disorders: Rash, alopecia.
Potentially Fatal: Lactic acidosis, severe hepatomegaly with steatosis; severe acute exacerbations of hepatitis B following treatment discontinuation.
Chỉ số theo dõi
Screen for HIV status prior therapy initiation. Monitor LFTs periodically during treatment and several months after discontinuation. Assess for signs and symptoms of lactic acidosis and hepatotoxicity.
Tương tác
Concomitant use with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either medicinal product.
Tương tác với thức ăn
Decreased absorption with food.
Tác dụng
Description: Entecavir is a nucleoside reverse transcriptase inhibitor which competes with natural substrates to inhibit hepatitis B viral polymerase enzyme thereby blocking reverse transcriptase activity thus reducing viral DNA synthesis.
Pharmacokinetics:
Absorption: Rapidly absorbed from the gastrointestinal tract. Decreased absorption with food. Time to peak plasma concentration: 30-90 minutes.
Distribution: Extensively distributed. Plasma protein binding: Approx 13%.
Metabolism: Partially metabolised in the liver via glucuronide or sulfate conjugation.
Excretion: Mainly via urine (60-73% as unchanged drug). Terminal elimination half-life: Approx 128-149 hours.
Đặc tính

Chemical Structure Image
Entecavir

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 135398508, Entecavir. https://pubchem.ncbi.nlm.nih.gov/compound/Entecavir. Accessed June 28, 2022.

Bảo quản
Store below 30°C. Protect from light. Use appropriate personal protective equipment (e.g. gloves) for receiving, handling, administration, and disposal. Storage instructions may vary among countries. Refer to specific product guidelines.
Phân loại MIMS
Thuốc kháng virus
Phân loại ATC
J05AF10 - entecavir ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Tài liệu tham khảo
Anon. Entecavir. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 05/05/2022.

Baraclude (DKSH Malaysia Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 05/05/2022.

Baraclude 0.05 mg/mL Oral Solution (Bristol-Myers Squibb Pharma EEIG). MHRA. https://products.mhra.gov.uk. Accessed 05/05/2022.

Baraclude 0.5 mg Film-coated Tablets (Bristol-Myers Squibb Pharma EEIG). MHRA. https://products.mhra.gov.uk. Accessed 05/05/2022.

Baraclude 1 mg Film-coated Tablets (Bristol-Myers Squibb Pharma EEIG). MHRA. https://products.mhra.gov.uk. Accessed 05/05/2022.

Baraclude Tablet, Film Coated, Solution (E.R. Squibb & Sons, L.L.C.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 05/05/2022.

Buckingham R (ed). Entecavir. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/05/2022.

Joint Formulary Committee. Entecavir. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/05/2022.

Novartis New Zealand Limited. Entecavir 0.5 mg and 1 mg Film-coated Tablet data sheet 03 December 2020. Medsafe. http://www.medsafe.govt.nz. Accessed 20/06/2022.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Entecavir từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Agicarvir
  • Baraclude
  • Caavirel
  • Enteclud
  • Hepariv
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in